.
Sorry Jag ... I read the article and did not see any reference to Admedus ... or did I read too fast and missed it?
Anyway, Boston and Edwards have just had their products approved and by the look of it Admedus has been left behinf.
There is now no reason for Edwards /Boston to bother paying anything for the Admedus product since their in-house existing products are approved.
Yes, the overall market just got a lot bigger, but nobody needs to buy TAVR valves from Admedus as far as I can see.
The only way might be if another company wants to buy its way into the market. Fingers crossed on that ...... does anyone know of any candidate medical supply companies who might fit that category?
.
.
Ann: Appendix 4C - quarterly, page-37
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.000(0.00%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.88 | $12.00 | $11.50 | $261.8K | 22.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 156 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 6045 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |